Kini SD, et al. - Data were estimated to quantify the utility of bevacizumab to manage epistaxis in subjects with hereditary hemorrhagic telangiectasias (HHT) and also to present the directions on its usage. They observed ineffective or invasive treatments with significant potential complications in the prevailing standard of care for HHT-related epistaxis. They found submucosal bevacizumab with the efficiency to decrease the frequency, duration, and severity of epistaxis in individuals with HHT.